Lulirx Cream contains Luliconazole 1% w/w, a topical antifungal agent belonging to the imidazole class, indicated for the treatment of superficial fungal infections of the skin. Luliconazole exhibits potent fungicidal activity against dermatophytes, yeasts, and molds by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This cream is primarily prescribed for conditions such as tinea corporis, tinea cruris, and tinea pedis. The formulation ensures effective skin penetration and sustained antifungal action with once-daily application. Lulirx Cream is generally well tolerated, with minimal adverse effects; however, patients may occasionally experience local irritation, burning sensation, or erythema at the application site. It is contraindicated in individuals with known hypersensitivity to Luliconazole or any cream excipients. The cream should be applied to the affected area and surrounding skin after cleansing and drying, typically for a duration of 2 to 4 weeks depending on the infection type and clinical response. Patients are advised to complete the full course of therapy to prevent recurrence. Lulirx Cream is not intended for use in mucosal or ocular fungal infections and should be used under medical supervision.